Stockscreener 앱 받기
314.12
2.73%
-8.82
시간 외 거래:
314.00
-0.12
-0.04%
전일 마감가:
$322.94
열려 있는:
$322.32
하루 거래량:
406.95K
Relative Volume:
1.04
시가총액:
$14.38B
수익:
$2.76B
순이익/손실:
$1.11B
주가수익비율:
13.80
EPS:
22.77
순현금흐름:
$898.10M
1주 성능:
+3.19%
1개월 성능:
-15.75%
6개월 성능:
-8.31%
1년 성능:
+34.26%
1일 변동 폭
$313.98
$324.57
1주일 범위
$299.47
$324.57
52주 변동 폭
$221.53
$417.81
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
314.12 | 14.38B | 2.76B | 1.11B | 898.10M | 22.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.23 | 130.97B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.96 | 73.86B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
611.18 | 37.38B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.30 | 32.70B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
261.38 | 27.92B | 3.32B | -860.46M | -1.04B | -8.32 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia
For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review
United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com
What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan
Top Executives Cash In on United Therapeutics Stock! - TipRanks
Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com
United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada
United Therapeutics director Thompson sells $795,837 in stock - Investing.com India
Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow
Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World
Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat
Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares - MarketBeat
Atria Wealth Solutions Inc. Invests $412,000 in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics Corp. Reports Record Revenue and Growth - TipRanks
United Therapeutics Corp. to Host Earnings Call - ACCESS Newswire
United Therapeutics Reports Record Revenue in Q4 2024, Advances Strategic Growth - HPBL
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript - Insider Monkey
Goldman Sachs cuts United Therapeutics stock target to $293 By Investing.com - Investing.com Australia
Goldman Sachs cuts United Therapeutics stock target to $293 - Investing.com
United Therapeutics: Q4 Earnings Snapshot - Thehour.com
United Therapeutics Corp (UTHR) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus.com
United Therapeutics Reports Record 2024 Financial Results - TipRanks
United Therapeutics Enters Oversold Territory (UTHR) - Nasdaq
United Therapeutics (UTHR) Shares Cross Below 200 DMA - Nasdaq
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat - Yahoo Finance
Earnings call transcript: United Therapeutics Q4 2024 earnings miss impacts stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations - Yahoo Finance
United Therapeutics: Q4 Earnings Snapshot -February 26, 2025 at 06:49 am EST - Marketscreener.com
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-K Report - TradingView
GraniteShares Advisors LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
How United Therapeutics Drove 24% Revenue Growth in 2024Key Products and Pipeline Updates - StockTitan
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings - Yahoo Finance
United Therapeutics: A Unique Business With High Margins And Expansion Potential - Seeking Alpha
Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
United Therapeutics Corp expected to post earnings of $6.31 a shareEarnings Preview - TradingView
Can United Therapeutics' Next Strategic Move Transform Patient Care? Key Insights Coming March 3 - StockTitan
United Therapeutics Corporation (UTHR): Among Renaissance Technologies Portfolio’s Top Stock Picks - Insider Monkey
Vontobel Holding Ltd. Cuts Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Mar 10 '25 |
Sale |
320.09 |
2,000 |
640,184 |
0 |
1.18%
1.49%
자본화:
|
볼륨(24시간):